Morphoea in children

Török, É; E, Ablonczy

doi:10.1111/j.1365-2230.1986.tb00517.x

Cited by 21 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As has been referred in the literature, 1–8 in both SCS and PFH, females were predominant in our series. In 10 of 13 cases of SCS and in all with PFH, the initial lesions appeared during the first decade of life.…”

Section: Discussionsupporting

confidence: 75%

See 1 more Smart Citation

Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them?

Orozco‐Covarrubias¹,

Guzmán-Meza²,

Ridaura-Sanz³

et al. 2002

Acad Dermatol Venereol

View full text Add to dashboard Cite

The aim was to be able to evaluate the diagnosis of two diseases by a consensus of clinical opinion used in the Department of Dermatology of the National Institute of Paediatrics in Mexico City. To differentiate between scleroderma 'en coup de sabre' (SCS) and progressive facial hemiatrophy (PFH), colour slides of 13 patients diagnosed as SCS and nine as PFH were examined by two dermatologists and microscopic slides by two pathologists. In both cases, the slides were randomly presented and no clinical information was given. The clinical and histopathological findings were statistically compared with two-tailed tests and alpha = 0.05. Kappa coefficients were obtained to evaluate the concordance between dermatologists, pathologists, and in terms of the consensus diagnosis. The usefulness of photographic assessment is limited by the inability to palpate the consistency of lesions. The most important clinical feature that differentiated both conditions was cutaneous sclerosis present in eight of 13 patients with SCS and in none of the PFH patients (P < 0.005). Other clinical features more frequently found in SCS were cutaneous hyperpigmentation and alopecia. The more frequent clinical features in PFH were total hemifacial involvement and ocular changes. Statistically significant histopathological features were: connective tissue fibrosis present in all cases with SCS and two of nine patients with PFH (P < 0.0002); adnexal atrophy present in 11 of 13 patients with SCS, and in three of nine with PFH (P < 0.02), and mononuclear cell infiltrates in all patients with SCS cf. six with PFH (P < 0.05). Our results suggest that in most cases it is possible to differentiate SCS from PFH based on clinicopathological findings.

show abstract

Section: Discussionsupporting

confidence: 75%

“…The involved skin area is depressed, hard, hyperpigmented, shiny and devoid of hair. Facial asymmetry may result from underlying muscle and bone involvement 2 …”

Section: Introductionmentioning

confidence: 99%

Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them?

Orozco‐Covarrubias¹,

Guzmán-Meza²,

Ridaura-Sanz³

et al. 2002

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…We were able to uncover at least 20 previously described pediatric patients whose initial morphea evolved into lung, heart, esophageal, renal, or cutaneous manifestations of progressive systemic sclerosis. 11,12,17,20,[28][29][30][31][32][33][34] Some of these patients have been described without individual details; those 14 patients (including ours) with further information are presented in Table V. In an international collaborative study, 750 pediatric patients with morphea were described by primarily rheumatologists at 70 centers.…”

Section: Discussionmentioning

confidence: 96%

Pediatric morphea (localized scleroderma): Review of 136 patients

Christen‐Zaech

Hakim

Afşar

et al. 2008

Journal of the American Academy of Dermatology

245

290

View full text Add to dashboard Cite

“…Plaque‐like lesions of localized morphea tend to improve with time. In 63 of 88 children with morphea, lesions resolved with minimal cosmetic disability (10). The induration lessens and the lesions blend in with the rest of the skin, leaving a brownish stain, which may persist for a long time.…”

mentioning

confidence: 99%

Congenital Skin Lesions Presenting as Morphea in a 4‐year‐old

Joshi

Almutairi

Nour-Eldin

2006

Pediatric Dermatology

View full text Add to dashboard Cite

A 4-year-old boy with five asymptomatic, shiny plaques on his abdomen and chest, present since birth, was brought by his parents. He was born at term by normal vaginal delivery. There was no history of difficult or prolonged labor or use of forceps during delivery. The antenatal period was uneventful. He had no history of drug intake other than hematinics and calcium tablets taken by his mother during pregnancy. There was no history of similar lesions in the family. The parents were told that the lesions were birthmarks and these had been treated with emollients alone. The lesions increased in size proportionate to the growth of the child.His general physical and systemic examinations were within normal limits. Cutaneous examination revealed five, 3 × 4 to 8 × 6 cm ill defined, indurated plaques on the left half of the abdomen and chest (Fig. 1). The overlying skin was shiny, atrophic and could not be pinched. The skin over the periphery of the lesions was darker than the normal skin. There was no erythema in and around the lesions. A clinical diagnosis of morphea was made. Routine baseline investigations (complete blood cell count, ESR, clinical chemistries, and urinalysis) were normal. Serology for antinuclear antibodies, Borrelia burgdorferi , and TORCH (toxoplasmosis, other infections, rubella, cytomegalovirus infection, and herpes simplex) titers were negative in both the mother and the child.

show abstract

Morphoea in children

Cited by 21 publications

References 10 publications

Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them?

Scleroderma ‘en coup de sabre’ and progressive facial hemiatrophy. Is it possible to differentiate them?

Pediatric morphea (localized scleroderma): Review of 136 patients

Congenital Skin Lesions Presenting as Morphea in a 4‐year‐old

Contact Info

Product

Resources

About